PIMAVANSERIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pimavanserin, and when can generic versions of Pimavanserin launch?
Pimavanserin is a drug marketed by MSN and Zydus and is included in three NDAs.
The generic ingredient in PIMAVANSERIN is pimavanserin tartrate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PIMAVANSERIN?
- What are the global sales for PIMAVANSERIN?
- What is Average Wholesale Price for PIMAVANSERIN?
Summary for PIMAVANSERIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Clinical Trials: | 39 |
Patent Applications: | 353 |
DailyMed Link: | PIMAVANSERIN at DailyMed |
![PIMAVANSERIN drug patent expirations Drug patent expirations by year for PIMAVANSERIN](/p/graph/s/t/PIMAVANSERIN-patent-expirations.png)
Recent Clinical Trials for PIMAVANSERIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Kansas Medical Center | Phase 2 |
New York State Psychiatric Institute | Phase 2 |
Research Foundation for Mental Hygiene, Inc. | Phase 2 |
US Patents and Regulatory Information for PIMAVANSERIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msn | PIMAVANSERIN | pimavanserin tartrate | CAPSULE;ORAL | 214925-001 | Jan 16, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Zydus | PIMAVANSERIN | pimavanserin tartrate | CAPSULE;ORAL | 214493-001 | Jan 16, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zydus | PIMAVANSERIN | pimavanserin tartrate | TABLET;ORAL | 214502-001 | Jan 16, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |